Immunotherapy plus chemo aims to shrink stomach tumors before surgery

NCT ID NCT07522151

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy (S-1 and oxaliplatin) works better than chemo alone for people with stomach or gastroesophageal junction cancer that can be surgically removed. About 874 participants will receive the treatment or a placebo before and after surgery. The study measures how long patients live without cancer returning and how well the tumor responds to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Adebrelimab (an immunotherapy drug) plus S-1 and oxaliplatin (chemotherapy)
What this could lead to
If successful, this combination could become a new standard treatment to reduce cancer recurrence and improve survival for people with resectable gastric cancer.
What could go wrong
This is a large phase 3 trial, but immunotherapy can cause immune-related side effects. The benefit over standard chemo alone is not yet proven, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Cancer Hospital

    RECRUITING

    Beijing, Beijing Municipality, 10000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.